Geiger et al, AACC, 2010

1. Geiger et al, AACC, 2010 The clinical Laboratory’s critical role in decreasing Methicillin-resistant Staphylococcus aureus(MRSA) hospital acquired infection (HAI) by implementing a rapid screening program • Implementation of a high-risk surveillance [ICU,CCU (cardiac care unit), Orthopedic, Telemetry] patients with the Xpert® MRSA (2007- 2009) • Multi-disciplinaryteam had the common goal of reducing MRSA infections to zero

2. Economic and Patient Outcome Impact Cost-Benefit of Rapid Molecular Testing 2007 – 2009 MRSA infection rate : - 68% Savings of $1.7M Geiger et al, AACC, 2010

3. Screening benefits Geiger et al, AACC, 2010

4. ICU & CCU LOS decrease Geiger et al, AACC, 2010

5. 5 years later, Mather Hospital continues to realize cost savings and improved patient care

6. Geiger et al, AACC, 2012 The effectiveness of a Methicillin-Resistant Staphylococcus Aureus(MRSA) rapid screening program for high risk patients in reducing hospital acquired infections (HAIs) in a community hospital • 4 year follow up

7. Economic and Patient Outcome Impact Cost-Benefit of Rapid Molecular Testing 2007 – 2011 MRSA infection rate : - 82% Savings of $2.14M (86%) Geiger et al, AACC, 2012

8. Screening benefits Geiger et al, AACC, 2012

9. ICU & CCU LOS decrease Geiger et al, AACC, 2012

10. Conclusions • A four year retrospective review of our rapid surveillance high risk targeted MRSA screening program using Xpertachieved the following clinicaloutcomes: • Reduced the time to diagnosis by 95% compared with traditional microbiology culture, • Saved millions of dollars in hospitalization and infection costs associated with HAI’s, • Enhanced patient safety by reducing HAIs, • Complied with the implementation of evidence basedpractices to prevent HAI’s in acute care hospitals, • Dramatically reduced infection rates by 82% from 2007 pre-screening rates, • Decreased length of stay by 21%, • Improved bed management in the organization Geiger et al, AACC, 2012

11. Geiger et al, 2007-2011